Fintel reports that on February 4, 2025, Piper Sandler downgraded their outlook for Amphastar Pharmaceuticals (NasdaqGS:AMPH) ...

Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target to $36.00 ...

Piper Sandler downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $36, down from $66. The firm noted that shares of ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Amphastar Pharmaceuticals Inc (Symbol: AMPH) entered into oversold territory, hitting an RSI ...

Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, CA. This small manufacturing pharma concern is focused on making and distributing generic and proprietary injectable ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...

Amphastar Pharmaceuticals, Inc. (AMPH) stock price is 36.37 and Amphastar Pharmaceuticals, Inc. (AMPH) 10-day simple moving average is 36.33. Amphastar Pharmaceuticals, Inc. (AMPH) stock price is ...

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products ...

Ever wonder which ETFs do the best job at beating the benchmark index? This list is a good place to start.